Mycobacterium vaccae vaccine - Immune Network

Drug Profile

Mycobacterium vaccae vaccine - Immune Network

Alternative Names: V-7; V-7 Immunitor

Latest Information Update: 28 May 2015

Price : $50

At a glance

  • Originator Immune Network; Immunitor
  • Class Antituberculars; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Tuberculosis

Most Recent Events

  • 31 Oct 2013 Lisichanksk Regional Tuberculosis Dispensary plans a phase III trial for Tuberculosis (adjunctive treatment) in the Ukraine (NCT01977768)
  • 22 Aug 2012 Immune Network completes a phase II trial in Tuberculosis (adjunctive treament) in Ukraine (NCT01380119)
  • 10 Aug 2011 Phase-II clinical trials in Tuberculosis (adjunctive treatment) in Ukraine (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top